Cannara Biotech (LOVE) Q3 Investor Summit Group Virtual Conference 2025 earnings summary

Strategic positioning and operational highlights

• Operates over 1.6 million sq ft across two Quebec facilities, focusing on premium cannabis and vertical integration.

• Achieved a 26% increase in production capacity in the past year without additional capital costs.

• Holds the seventh largest producer position in Canada by sales and second in Quebec, with a 12.8% Quebec market share.

• Full control over supply chain enables quality assurance, efficiency, and margin protection.

• Expansion is possible within existing footprint, doubling capacity to 100,000 kg annually with minimal investment.

Financial performance and growth

• Posted $80 million net revenue and $32.7 million gross profit in the first nine months of 2025.

• Year-to-date gross margin reached 41%, with adjusted EBITDA of $20.7 million (26% of revenues).

• Net income for nine months was $9.8 million, a 53% increase over the previous year.

• Generated $17.2 million in operating cash flow and $12.3 million in free cash flow in nine months.

• Maintains a strong balance sheet with $14.4 million cash and a current ratio of 2.4.

Capital management and shareholder structure

• Over 50% insider ownership, with top 10 shareholders controlling over 70% of the float.

• No dilutive capital raises since 2021; share increases mainly from employee stock plans.

• Market cap of $157 million as of September 12, 2025, with a $1.73 closing price.

• Reduced term debt from $34 million to $28.5 million through asset sale and repayments.

• Upsized credit facility by $10 million for 2026 CAPEX, with interest rates reduced to below 6%.